Roche's Tecentriq combo shows promise in first-line triple-negative breast cancer

Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of advanced triple-negative breast cancer (TNBC).
The findings showed that the combination of ipatasertib, Tecentriq (atezolizumab) and chemotherapy (paclitaxel or nab-paclitaxel (Abraxane [paclitaxel albumin-bound particles for injectable suspension]) delivered an objective response rate (ORR) of 73% in the study’s 26 participants, regardless of tumour biomarker status.
“We are enthusiastic about the potential of this combination in triple-negative breast cancer, an aggressive type of breast cancer,” commented Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “These early results support the contribution of ipatasertib to our combination treatment approach in TNBC and reinforce our vision to develop medicines that may benefit patients with this challenging disease.”
Roche confirmed that a multi-centre Phase 3 study into the efficacy of Tecentriq, ipatasertib, and paclitaxel in the treatment of locally advanced/metastatic triple-negative breast cancer will launch later this year.
Matt Fellows
- Login or register to post comments
- Printer-friendly version
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
Related content
- NICE rejects Roche's immunotherapy Tecentriq in unresectable metastatic triple A breast cancer
- Roche's Tecentriq plus chemo shows promise in first-line, advanced bladder cancer
- Roche's breast, lung cancer offerings fail to impress at ASCO
- Roche's Tecentriq improves pathological complete response in triple-negative breast cancer at Phase 3
- Roche's Tecentriq falls short as an adjuvant monotherapy in muscle-invasive urothelial cancer